Auteurs
Ashutosh Tiwari, Utkarsha Paithane, Jordan Friedlein, Kojiro Tashiro, Olivier Saulnier, Karina Barbosa, Quang Trinh, Bryan Hall, Shrawantee Saha, Aditi Soni, Takuma Nakashima, Andrey Bobkov, Lynn Miya Fujimoto, Rabi Murad, Svetlana Maurya, Mayank Saraswat, Shahab Sarmashghi, Joshua T. Lange, Sihan Wu, Meher Beigi Masihi, Srija Ghosh, Gazal Hemmati, Owen Chapman, Liam Hendrikse, Brian James, Jens Luebeck, Tanja Eisemann, Theophilos Tzaridis, Deepak Rohila, Robyn Leary, Jyotika Varshney, Badrinath Konety, Scott M. Dehm, Yasuhiko Kawakami, Rameen Beroukhim, David A Largaespada, Lincoln Stein, Lukas Chavez, Hiromichi Suzuki, William A Weiss, Jianhua Zhao, Aniruddha Deshpande, Robert J. Wechsler-Reya, Michael D. Taylor, Anindya Bagchi
Résumé
ABSTRACT
MYC-driven (MYC+) cancers are aggressive and often fatal. MYC dysregulation is a key event in these cancers, but overexpression of MYC alone is not always enough to cause cancer.Plasmocytoma Variant Translocation 1(PVT1), a long non-coding RNA (lncRNA) adjacent to MYC on chromosome 8 is a rearrangement hotspot in many MYC+ cancers. In addition to being co-amplified with MYC, the genomic rearrangement at PVT1 involves translocation, which has had obscure functional consequences. We report that translocation at the PVT1 locus cause asymmetric enrichment of 5’-PVT1 and loss of 3’-PVT1. Despite being classified as a non-coding RNA, the retained 5’ region of PVT1 generates a circular RNA (CircPVT1) that codes for the novel peptide we call Firefox (FFX). FFX augments AKT signaling and synergistically activates MYC and mTORC1 in these cells. Further, the 3’ end of PVT1, which is lost during the translocation, codes for a tumor-suppressing micropeptide we named as Honeybadger (HNB). We demonstrate that HNB interacts with KRAS and disrupts the activation of KRAS effectors. Loss of HNB leads to activation of RAS/MAPK signaling pathway, and enhances MYC stability by promoting phosphorylation of MYC at Ser62. These findings identify PVT1 as a critical node that synchronizes MYC, AKT, and RAS-MAPK activities in cancer. Our study thus identifies a key mechanism by which rearrangements at the PVT1 locus activate additional oncogenic pathways that synergize with MYC to exacerbate the aggressiveness of MYC+ cancers. This newfound understanding explains the poor prognosis associated with MYC+ cancers and offers potential therapeutic targets that could be leveraged in treatment strategies for these cancers.
